<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals has filed an annual disclosure confirming it does not qualify as a 'Large Corporate' under SEBI regulations as of March 31, 2026. The company states that the specified criteria for Large Corporate classification are not applicable to it. In the accompanying Annexure-A, all borrowing-related fields are marked as 'Not applicable', indicating the company does not have outstanding borrowings meeting the threshold. This is a routine regulatory compliance filing under SEBI's framework for large corporate disclosures, with a two-year block period specified as FY 2026-27.
No direct impact on shareholders or stock price. This is a routine compliance filing that confirms Lincoln Pharmaceuticals falls below the threshold for Large Corporate classification, indicating it is likely a smaller mid-cap or small-cap company without significant outstanding borrowings.